κ-opioids induce a reversible inhibition of CFU-GM from CD133⁺ cord blood cells

References

• Morrison S, Shah M, Anderson D. Regulatory mechanisms in stem cell biology. Cell 1997; 88: 287–98
   PubMed Web of Science ®Google Scholar
• Hao Q, Shah A, Thiemann F, et al. A functional comparison of CD34+CD38− cells in cord blood and bone marrow. Blood 1995; 86: 3745–53
   PubMed Web of Science ®Google Scholar
• Miraglia S, Godfrey W, Yin A, et al. A novel five-transmembrane hematopoietic stem cell antigen:isolation, characterization and molecular cloning. Blood 1997; 90: 5013–21
   PubMed Web of Science ®Google Scholar
• Testa U, Torelli G, Riccioni R, et al. Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. Blood 2002; 99: 4634–37
   PubMed Web of Science ®Google Scholar
• Horn P, Tesch H, Staib P, et al. Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood 1999; 93: 1435–37
   PubMed Web of Science ®Google Scholar
• Kratz-Albers K, Zuhlsdorp M, Leo R, et al. Expression of AC133, a novel stem cell marker, on human leukemic blasts lacking CD34− antigen and on a human CD34+ leukemic line: MUTZ-2. Blood 1998; 92: 4485–87
   PubMed Web of Science ®Google Scholar
• Waller C, Martens U, Lange W. Philadelphia chromosome-positive cells are equally distributed in AC133+ and AC133− fractions of CD34+ peripheral blood progenitor cells from patients with CML. Leukemia 1999; 13: 1466–67
   PubMed Web of Science ®Google Scholar
• Yin A, Miraglia S, Zanjani E, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002–12
   PubMed Web of Science ®Google Scholar
• Quesenberry P, Colvin G. Hematopoietic stem cells, progenitor cells and cytokines. Williams Hematology, LM Beutler, E Coller, BS Kipps, TJ Seligsohn. McGraw-Hill, New York 2001; 153–87
   Google Scholar
• Horowitz D, Callahan J, Pelus, et al. Inhibition of hematopoietic progenitor cell growth by Tyr-MIF, an endogenous opiate modulator, and its degradation products. Int Immunopharmacol 2002; 2: 721–30
   PubMed Web of Science ®Google Scholar
• Calvo C, Cesselin F, Gelman M, Glowinski J. Identification of an opioid peptide secreted by rat embryonic mixed brain cells as a promoter of macrophage migration. Eur J Neurosc 2000; 12: 2676–84
   PubMed Web of Science ®Google Scholar
• Hauser K, Gurwell J, Bhat N. Endogenous opioid systems and the growth of oligodendrocyte progenitors: paradoxical increases in oligodendrogenesis as an indirect mechanism of opioid action. Glia 1993; 9: 157–62
   PubMed Web of Science ®Google Scholar
• Tryoen-Toth P, Gaveriaux-Ruff C, Maderspach K, Labourdette G. Regulation of kappa-opioid receptor mRNA level by cyclic AMP and growth factors in cultured rat glial cells. Mol Brain Res 1998; 55: 141–50
   PubMedGoogle Scholar
• Ventura C, Maioli M. Opioid peptide gene expression primes cardiogenesis in embryonal pluripotent stem cells. Circ Res 2000; 87: 189–94
   PubMed Web of Science ®Google Scholar
• Hytrek S, McLaughlin P, Lang C, Zagon I. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Letters 1996; 101: 159–64
   PubMed Web of Science ®Google Scholar
• Kikuchi Y, Kita T, Miyauchi M, et al. Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones. Gynecol Oncol 1989; 32: 60–4
   PubMed Web of Science ®Google Scholar
• Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line is partially mediated through opioid receptors. Eur J Pharmacol 1996; 296: 199–207
   PubMed Web of Science ®Google Scholar
• Zagon I, Hytrek S, McLaughlin P. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 1996; 271: R511–18
   PubMedGoogle Scholar
• Kampa M, Bakogeorgou E, Hatzoglou A, et al. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol 1997; 335: 255–65
   PubMed Web of Science ®Google Scholar
• Denning-Kendall P, Donaldson C, Nicol A, et al. Optimal processing of human umbilical cord blood for clinical banking. Exp Hematol 1996; 24: 1394–401
   PubMed Web of Science ®Google Scholar
• Kampa M, Loukas S, Hatzoglou A, et al. Identification of a novel opioid peptide derived from alpha-S1 human casein (alpha-S1 casomorphin, and alpha-S1 casomorphin-amide). Biochem J 1996; 319: 903–8
   PubMed Web of Science ®Google Scholar
• Kampa M, Hatzoglou A, Notas G, et al. Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. Cell Death Diff 2001; 8: 943–52
   PubMed Web of Science ®Google Scholar
• Coutinho L, Gilleece M, de Wynter E, . Clonal and long-term cultures using human bone marrow. Hemopoiesis: A Practical Approach, NG Testa, et al. Oxford University Press, Oxford 1993; 75–84
   Google Scholar
• Gordon MY, Marley SB, Lewis JL, et al. Treatment with interferon- (preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest 1998; 102: 710–15
   PubMed Web of Science ®Google Scholar
• Marley SB, Lewis JL, Davidson RJ, et al. Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children. Br J Haematol 1999; 106: 162–6
   PubMed Web of Science ®Google Scholar
• Jordan N, Kolios G, Abbot S, et al. Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. J Clin Invest 1999; 104: 1061–9
   PubMed Web of Science ®Google Scholar
• Rozen, S, Skaletsky, H. Primer 3 on the WWW for general. Humana Press, 2000: 365–86
   Google Scholar
• Talme T, Ivanoff J, Hagglund M, et al. Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3. Clin Exp Immunol 2001; 125: 71–9
   PubMed Web of Science ®Google Scholar
• Dimitriou H, Vorgia P, Stiakaki E, et al. In vitro proliferative and differentiating characteristics of CD133+ and CD34+ cord blood cells in the presence of thrombopoietin (TPO) or erythropoietin (EPO). Potential implications for hematopoietic cell transplantation. Leuk Res 2003; 27: 1143–51
   PubMed Web of Science ®Google Scholar
• Hatzoglou A, Kampa M, Castanas E. Opioid–somatostatin interactions in regulating cancer cell growth. Front Biosc 2005; 10: 244–56
   PubMed Web of Science ®Google Scholar
• Roy S, Ramakrishnan S, Loh H, Lee N. Chronic morphine treatment selectively suppresses macrophage colony formation in bone marrow. Eur J Pharmacol 1991; 195: 359–63
   PubMed Web of Science ®Google Scholar
• Krizanac-Bengez L, Boranic M, Testa N. Naloxone behaves as opioid agonist/antagonist in clonal cultures of mouse bone marrow cells. Biomed Pharmacoth 1995; 49: 27–31
   PubMed Web of Science ®Google Scholar
• Rozenfeld-Granot G, Toren A, Amariglio A, et al. MAP kinase activation by mu opioid receptor in cord blood CD34(+)CD38(−) cells. Exp Hematol 2002; 30: 473–80
   PubMed Web of Science ®Google Scholar
• Hatzoglou A, Ouafik L, Bakogeorgou E, et al. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. Cancer Res 1995; 55: 5632–6
   PubMed Web of Science ®Google Scholar
• Kampa M, Hatzoglou A, Thermos K, Castanas E. Direct interaction of opioids with alpha1 adrenergic receptors in the human prostate cancer cell line LNCaP. Action on cell proliferation. HSBMB Newsletters 1999; 46: 30–5
   Google Scholar
• Wu W, Zheng J, Li Y, Zhang K, Bai H. Involvement of mu-opioid receptors and alpha-adrenoreceptors in the immunomodulatory effects of dihydroetorphine. Eur J Pharmacol 1998; 353: 79–85
   PubMed Web of Science ®Google Scholar
• Maneckjee R, Minna J. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Diff 1994; 5: 1033–40
   PubMedGoogle Scholar
• Sueoka E, Sueoka N, Kai Y, et al. Anticancer activity of morphine and its synthetic derivative, KT-90, mediated through apoptosis and inhibition of NF-kappaB activation. Biochem Biophys Res Commun 1998; 252: 566–70
   PubMed Web of Science ®Google Scholar